share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募资说明书
美股SEC公告 ·  07/31 12:37

Moomoo AI 已提取核心信息

Panbela Therapeutics has filed a prospectus supplement on July 30, 2024, to update information related to the resale of 255,600 shares of common stock by selling securityholders, as part of its registration statement on Form S-1. The supplement follows a current report on Form 8-K filed on the same date, detailing a new loan agreement entered into on July 24, 2024, between Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., with USWM, LLC. The loan agreement provides a term loan of $1.5 million with specific interest and premium terms, maturing on the earliest of a qualifying financing or transaction closing, or December 31, 2024. The proceeds are designated for payment of fees and expenses to a contract research organization, working capital purposes, and related fees or expenses. The company has also entered into a security agreement granting USWM, LLC a first priority security interest in all rights, title, and interest in the Asset Purchase Agreement to secure the obligations under the loan.
Panbela Therapeutics has filed a prospectus supplement on July 30, 2024, to update information related to the resale of 255,600 shares of common stock by selling securityholders, as part of its registration statement on Form S-1. The supplement follows a current report on Form 8-K filed on the same date, detailing a new loan agreement entered into on July 24, 2024, between Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., with USWM, LLC. The loan agreement provides a term loan of $1.5 million with specific interest and premium terms, maturing on the earliest of a qualifying financing or transaction closing, or December 31, 2024. The proceeds are designated for payment of fees and expenses to a contract research organization, working capital purposes, and related fees or expenses. The company has also entered into a security agreement granting USWM, LLC a first priority security interest in all rights, title, and interest in the Asset Purchase Agreement to secure the obligations under the loan.
panbela therapeutics于2024年7月30日提交招股说明书补充，更新关于出售安防-半导体方面股东255,600股普通股的信息，作为其S-1表格注册声明的一部分。该补充遵循同一日期提交的8-K表格的最新报告，详细说明了panbela therapeutics与其子公司cancer prevention pharmaceuticals, inc.与USWm, LLC之间于2024年7月24日达成的新贷款协议。该贷款协议提供了150万美元的定期贷款，具有特定的利率和溢价条款，最迟于符合融资或交易结束的时间前，或2024年12月31日到期。所得款项用于支付合同研究组织的费用和支出、营运资金目的及相关费用或支出。该公司还签订了一个安全协议，授予USWm, LLC对资产购买协议中的所有权利、标题和利益的首要安全利益，以确保履行贷款的义务。
panbela therapeutics于2024年7月30日提交招股说明书补充，更新关于出售安防-半导体方面股东255,600股普通股的信息，作为其S-1表格注册声明的一部分。该补充遵循同一日期提交的8-K表格的最新报告，详细说明了panbela therapeutics与其子公司cancer prevention pharmaceuticals, inc.与USWm, LLC之间于2024年7月24日达成的新贷款协议。该贷款协议提供了150万美元的定期贷款，具有特定的利率和溢价条款，最迟于符合融资或交易结束的时间前，或2024年12月31日到期。所得款项用于支付合同研究组织的费用和支出、营运资金目的及相关费用或支出。该公司还签订了一个安全协议，授予USWm, LLC对资产购买协议中的所有权利、标题和利益的首要安全利益，以确保履行贷款的义务。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间